Secondary malignancies after treatment of testicular germ cell tumors: a systematic review and meta-analysis.
Level 3 - non-randomized controlled study
Systematic review and meta-analysis of observational cohort studies
PubMed 40221864 · doi:10.1093/jnci/djaf099
What was done
A systematic review and meta-analysis of Medline, EMBASE, and Cochrane databases was conducted to evaluate the risk of secondary malignant neoplasms in patients treated for testicular germ cell tumors. The primary outcome was the diagnosis of any non-germ cell secondary malignant neoplasm compared to the general population, analyzed with random-effects models calculating standardized incidence ratios (SIRs). Evidence certainty was evaluated using the GRADE framework.
What was found
The meta-analysis included 21 studies covering 88,863 patients and 5,180 secondary malignant neoplasms with a median follow-up of 12.5 years. Surgery alone showed no increased risk of non-germ cell secondary malignancies (SIR = 0.99, 95% CI = 0.84 to 1.17). In contrast, risk was significantly increased after radiation alone (SIR = 1.66, 95% CI = 1.43 to 1.93), chemotherapy alone (SIR = 1.65, 95% CI = 1.39 to 1.96), and combined chemotherapy and radiation (SIR = 2.73, 95% CI = 2.23 to 3.33). Quality of evidence was rated as low to moderate certainty by GRADE.
Why it matters
Because testicular cancer has high long-term survival rates, quantifying treatment-specific risks of secondary cancers helps clinicians and patients weigh initial therapeutic strategies and design tailored long-term survivorship surveillance.
Limits
The included literature consists of observational studies subject to confounding and yielded low to moderate GRADE certainty. The abstract does not report specific chemotherapy regimens, radiation doses, anatomical sites of secondary malignancies, or detailed patient baseline characteristics.
Cited by
- supports Radiation and chemotherapy treatments are major risk factors for cancer recurrence and the development of secondary malignancies.